All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
CAT | Product Name | Target Species | Antibody Clone | Antibody Host | Receptor Construction | Vector Type | Targeting Cell Type | CAR Vector Type | Inquiry & Datasheet |
XS-0822-LX55 | Anti-GUCY2C (X8X55) h(CD28-41BB-CD3ζ) CAR, pCDCAR1 | Human | X8X55 | Mouse | scFv-CD28-41BB-CD3ζ | Lentiviral vector | T cell | ||
XS-0822-LX237 | Anti-GUCY2C (X8X50) h(CD28-OX40-CD3ζ) CAR, pCDCAR1 | Human | X8X50 | Mouse | scFv-CD28-OX40-CD3ζ | Lentiviral vector | T cell | ||
XS-0822-LX238 | Anti-GUCY2C (X8X51) h(CD28-OX40-CD3ζ) CAR, pCDCAR1 | Human | X8X51 | Mouse | scFv-CD28-OX40-CD3ζ | Lentiviral vector | T cell | ||
XS-0822-LX423 | Anti-GUCY2C (X8X49) h(ICOS-41BB-CD3ζ) CAR, pCDCAR1 | Human | X8X49 | Mouse | scFv-ICOS-4-1BB-CD3ζ | Lentiviral vector | T cell | ||
XS-0822-LX424 | Anti-GUCY2C (X8X50) h(ICOS-41BB-CD3ζ) CAR, pCDCAR1 | Human | X8X50 | Mouse | scFv-ICOS-4-1BB-CD3ζ | Lentiviral vector | T cell | ||
XS-0822-LX425 | Anti-GUCY2C (X8X51) h(ICOS-41BB-CD3ζ) CAR, pCDCAR1 | Human | X8X51 | Mouse | scFv-ICOS-4-1BB-CD3ζ | Lentiviral vector | T cell | ||
XS-0822-YF2333 | Anti-Human GUCY2C (XW-493) h(CD28-41BB-CD3ζ) CAR IVT Plasmid, pCARIVT | Human | XW-493 | Mouse | scFv-CD28-41BB-CD3ζ | In Vitro Transcription (IVT) Vector | |||
XS-0822-YF2334 | Anti-Human GUCY2C (XW-494) h(CD28-41BB-CD3ζ) CAR IVT Plasmid, pCARIVT | Human | XW-494 | Human | scFv-CD28-41BB-CD3ζ | In Vitro Transcription (IVT) Vector | |||
XS-0822-YF8573 | TS-Fluc Anti-Human GUCY2C scFv (XW-493) CD28-CD3ζ CAR, pCDCAR1 | Human | XW-493 | Mouse | 7H-YB-Fluc-EF1a-scFv-CD28-CD3ζ | Lentiviral vector | |||
XS-0822-YF8574 | TS-Fluc Anti-Human GUCY2C scFv (XW-494) CD28-CD3ζ CAR, pCDCAR1 | Human | XW-494 | Human | 7H-YB-Fluc-EF1a-scFv-CD28-CD3ζ | Lentiviral vector | |||
XS-0822-YF8982 | TS-Fluc Anti-Human GUCY2C scFv (XW-493) 41BB-CD3ζ CAR, pCDCAR1 | Human | XW-493 | Mouse | 7H-YB-Fluc-EF1a-scFv-41BB-CD3ζ | Lentiviral vector | |||
XS-0822-YF8983 | TS-Fluc Anti-Human GUCY2C scFv (XW-494) 41BB-CD3ζ CAR, pCDCAR1 | Human | XW-494 | Human | 7H-YB-Fluc-EF1a-scFv-41BB-CD3ζ | Lentiviral vector | |||
XS-0822-YF9391 | TS-Fluc Anti-Human GUCY2C scFv (XW-493) CD28-41BB-CD3ζ CAR, pCDCAR1 | Human | XW-493 | Mouse | 7H-YB-Fluc-EF1a-scFv-CD28-41BB-CD3ζ | Lentiviral vector | |||
XS-0822-YF9392 | TS-Fluc Anti-Human GUCY2C scFv (XW-494) CD28-41BB-CD3ζ CAR, pCDCAR1 | Human | XW-494 | Human | 7H-YB-Fluc-EF1a-scFv-CD28-41BB-CD3ζ | Lentiviral vector | |||
XS-0822-YF9800 | TS-IL15 SA Anti-Human GUCY2C scFv (XW-493) CD28-CD3ζ CAR, pCDCAR1 | Human | XW-493 | Mouse | 7H-YB-IL15 SA-EF1a-scFv-CD28-CD3ζ | Lentiviral vector | |||
XS-0822-YF9801 | TS-IL15 SA Anti-Human GUCY2C scFv (XW-494) CD28-CD3ζ CAR, pCDCAR1 | Human | XW-494 | Human | 7H-YB-IL15 SA-EF1a-scFv-CD28-CD3ζ | Lentiviral vector | |||
XS-0822-YF10209 | TS-IL15 SA Anti-Human GUCY2C scFv (XW-493) 41BB-CD3ζ CAR, pCDCAR1 | Human | XW-493 | Mouse | 7H-YB-IL15 SA-EF1a-scFv-41BB-CD3ζ | Lentiviral vector | |||
XS-0822-YF10210 | TS-IL15 SA Anti-Human GUCY2C scFv (XW-494) 41BB-CD3ζ CAR, pCDCAR1 | Human | XW-494 | Human | 7H-YB-IL15 SA-EF1a-scFv-41BB-CD3ζ | Lentiviral vector | |||
XS-0822-YF10618 | TS-IL15 SA Anti-Human GUCY2C scFv (XW-493) CD28-41BB-CD3ζ CAR, pCDCAR1 | Human | XW-493 | Mouse | 7H-YB-IL15 SA-EF1a-scFv-CD28-41BB-CD3ζ | Lentiviral vector | |||
XS-0822-YF10619 | TS-IL15 SA Anti-Human GUCY2C scFv (XW-494) CD28-41BB-CD3ζ CAR, pCDCAR1 | Human | XW-494 | Human | 7H-YB-IL15 SA-EF1a-scFv-CD28-41BB-CD3ζ | Lentiviral vector |
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION